Dilaudid (Hydromorphone HCl) Patent Expiration, LOE Window & CMS Spending
Dilaudid (Hydromorphone HCl) by Fresenius Kabi: FDA Orange Book LOE 2034-03-12, 6 AB generics, $399K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | N019034 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2034-03-12 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $399K |
| 2024 Medicare Part D Spend | $350K |
| 2024 Medicaid Spend | $49K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.